Skip header and navigation

Refine By

236 records – page 1 of 24.

A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis.

https://arctichealth.org/en/permalink/ahliterature14307
Source
Ann Rheum Dis. 1996 Mar;55(3):169-76
Publication Type
Article
Date
Mar-1996
Author
G. Bendix
A. Bjelle
Author Affiliation
Department of Rheumatology, Gothenburg University, Sweden.
Source
Ann Rheum Dis. 1996 Mar;55(3):169-76
Date
Mar-1996
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Antirheumatic Agents - administration & dosage - adverse effects - therapeutic use
Arthritis, Rheumatoid - drug therapy
Comparative Study
Drug Tolerance
Female
Follow-Up Studies
Gold Sodium Thiomalate - administration & dosage - adverse effects - therapeutic use
Humans
Injections, Intravenous
Male
Middle Aged
Probability
Research Support, Non-U.S. Gov't
Retrospective Studies
Sweden
Abstract
OBJECTIVES: To study the long term tolerance of parenteral gold and subsequent drug treatment in patients with rheumatoid arthritis, including prediction of outcome and 'survival' of sequential treatments. METHODS: A retrospective cohort study of 376 patients was made, including a detailed screening of 237 patients treated in 1989. Reasons for discontinuing treatment were analysed in life table analyses, which were used to compare patients receiving parenteral gold treatment in 1985 and 1989, and two groups of patients receiving disease modifying antirheumatic drugs after parenteral gold treatment. The causes of discontinuation were followed in sequential treatments. RESULTS: The estimated probability of discontinuation of parenteral gold treatment was 29% after six months and 42%, 55%, 74%, and 92% after 1, 2, 5, and 10 years, respectively. Mucocutaneous side effects were the main cause of discontinuation of parenteral gold treatment during the first three years, while the probability of discontinuation because of inefficacy dominated after four years. Side effects also constituted the main cause of discontinuation of treatments given after parenteral gold treatment during the first three years of follow up. No significant differences were found when comparing the termination rates between the first and the second and subsequent treatments after parenteral gold treatment. The main reasons for discontinuing one treatment could not predict the cause of discontinuation of the next treatment. CONCLUSION: Mucocutaneous side effects dominated initially, while inefficacy was the dominating cause of discontinuation of long term parenteral gold treatment. No serious side effects were registered. The cause of discontinuation of one treatment did not predict the cause of discontinuation of the following drug. Drug 'survival' was the same in both treatments after parenteral gold treatment.
PubMed ID
8712879 View in PubMed
Less detail

[Abuse of intravenously injected drugs among persons arrested by the Stockholm police from 1965 to 1968].

https://arctichealth.org/en/permalink/ahliterature110222
Source
Lakartidningen. 1969 Feb 19;66(8):781-6
Publication Type
Article
Date
Feb-19-1969
Author
N. Bejerot
Source
Lakartidningen. 1969 Feb 19;66(8):781-6
Date
Feb-19-1969
Language
Swedish
Publication Type
Article
Keywords
Adolescent
Adult
Female
Humans
Injections, Intravenous
Male
Social Problems
Substance-Related Disorders - epidemiology
Sweden
PubMed ID
5769219 View in PubMed
Less detail

[Accidental administration of racemic adrenaline. Three life-threatening cases after intravenous injection in children]

https://arctichealth.org/en/permalink/ahliterature10909
Source
Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1080-1
Publication Type
Article
Date
Mar-10-1998
Author
B. Zeller
H J Bangstad
Author Affiliation
Barneavdelingen, Sentralsykehuset i Akershus, Nordbyhagen.
Source
Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1080-1
Date
Mar-10-1998
Language
Norwegian
Publication Type
Article
Keywords
Child
Emergencies
English Abstract
Epinephrine - administration & dosage - adverse effects
Humans
Infant
Injections, Intravenous
Lung Diseases, Obstructive - drug therapy
Male
Medication Errors
Nebulizers and Vaporizers
Abstract
The inhalation of racemic adrenalin is an important part of the treatment of inflammatory airway obstruction in children. In Norway during the last few years there have been several cases of adrenal solutions intended only for inhalation being accidentally administered as intravenous injections. The solution for inhalation contains an adrenalin concentration 110 times greater than the adrenalin intended for emergency use (0.1 mg/ml). The instant consequences of intravenous injections of inhalation adrenalin include arterial hypertension followed by hypotension, cardiac ischemia and cardiac insufficiency, pulmonary oedema, and respiratory failure and the need for artificial ventilation. The clinical picture in the three patients we describe was very dramatic. The injected doses were 0.16-1.1 mg l-adrenalin per kg body weight. All children survived without sequelae. In order to reduce the risk of accidentally administering intravenous injections of adrenalin intended for inhalation a set of guidelines is being proposed.
PubMed ID
9531834 View in PubMed
Less detail

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.

https://arctichealth.org/en/permalink/ahliterature136584
Source
Scand J Urol Nephrol. 2011 Apr;45(3):196-205
Publication Type
Article
Date
Apr-2011
Author
Anders Fernström
Jan Giæver
Barbara Granroth
Britta Hylander
Gert Jensen
Anders Christensson
Björn Wikström
Lars Weiss
Ulf Wrege
Stefan H Jacobson
Author Affiliation
Department of Nephrology, Linköping University/Linköping University Hospital, Linköping, Sweden. anders.fernstrom@lio.se
Source
Scand J Urol Nephrol. 2011 Apr;45(3):196-205
Date
Apr-2011
Language
English
Publication Type
Article
Keywords
Aged
Biomarkers, Pharmacological - blood - metabolism
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage - pharmacology - therapeutic use
Bone Diseases, Metabolic - drug therapy - etiology - metabolism
Bone and Bones - metabolism
Calcium - blood
Chronic Disease
Ergocalciferols - administration & dosage - pharmacology - therapeutic use
Female
Humans
Hyperparathyroidism, Secondary - complications - drug therapy - metabolism
Injections, Intravenous
Kidney Diseases - complications - metabolism - therapy
Male
Middle Aged
Observation
Parathyroid Hormone - metabolism
Phosphorus - blood
Prospective Studies
Renal Dialysis
Sweden
Abstract
Secondary hyperparathyroidism (SHPT) is a common problem among patients with chronic kidney disease (CKD) on haemodialysis. This study was conducted to assess the use, effectiveness and safety of intravenous paricalcitol in haemodialysis patients with various degrees of SHPT.
This observational, multicentre, prospective study was conducted in 14 Swedish dialysis centres from May 2007 to June 2008 and included 92 haemodialysis patients with a diagnosis of SHPT associated with CKD. The decision to initiate treatment with intravenous paricalcitol was made by the treating physician. No treatment algorithms were provided.
Mean patient age was 64 years. Of the 92 patients included, 74 had an intact parathyroid hormone (iPTH) level of >300 pg/ml at baseline. Median iPTH was 584 pg/ml in patients with a baseline PTH of >300 pg/ml. During follow-up there was a decrease in iPTH to 323 pg/ml at 6 months (-45%, p
PubMed ID
21366390 View in PubMed
Less detail

[A comparative evaluation of the efficacy of peroral and intravenous pulse therapy with methylprednisolone in rheumatic diseases]

https://arctichealth.org/en/permalink/ahliterature14180
Source
Lik Sprava. 1998 Oct-Nov;(7):48-52
Publication Type
Article
Author
K M Amosova
O B Iaremenko
O V Potapkov
N A Ivashchenko
Source
Lik Sprava. 1998 Oct-Nov;(7):48-52
Language
Ukrainian
Publication Type
Article
Keywords
Administration, Oral
Adult
Antirheumatic Agents - administration & dosage - adverse effects
Chi-Square Distribution
Chronic Disease
Comparative Study
Drug Evaluation
English Abstract
Female
Humans
Injections, Intravenous
Male
Methylprednisolone - administration & dosage - adverse effects
Rheumatic Diseases - blood - drug therapy
Statistics, nonparametric
Abstract
Pulse therapy with methylprednisolone (Solu-Medrol, Upjohn), 1000 mg daily over three successive days, was administered to patients in two randomized groups of 14 patients in each (23 patients with systemic lupus erythematosus, 5 with rheumatoid arthritis). In one of the groups the drug was taken per os, the other received it intravenously. There was no significant difference between the two groups in terms of clinical effectiveness and incidence of side effects However, the time-related course of such indices as erythrocyte sedimentation rate, the level of leukocytes, of total protein, urea, the blood antioxidant potential, permeability of erythrocytic membranes and capillary and tissue barrier proteinuria as well as the content of immune complexes in the arterial and venous blood was more striking with per os intake. Of the 14 patients, 11 demonstrated short-continued asymptomatic 35% rise in the activity of alaninaminotransferase.
PubMed ID
10050456 View in PubMed
Less detail

Acute intravenous and long-term oral hemodynamic effects of encainide.

https://arctichealth.org/en/permalink/ahliterature55611
Source
Am J Cardiol. 1986 Aug 29;58(5):25C-30C
Publication Type
Article
Date
Aug-29-1986
Author
M H Sami
Source
Am J Cardiol. 1986 Aug 29;58(5):25C-30C
Date
Aug-29-1986
Language
English
Publication Type
Article
Keywords
Administration, Oral
Adult
Aged
Anilides - administration & dosage - therapeutic use
Anti-Arrhythmia Agents - administration & dosage - therapeutic use
Arrhythmia - drug therapy
Blood Pressure - drug effects
Encainide
Female
Heart Rate - drug effects
Heart Ventricles
Hemodynamic Processes - drug effects
Humans
Injections, Intravenous
Male
Middle Aged
Stroke Volume - drug effects
Time Factors
Abstract
The short- and long-term hemodynamic effects of encainide, a new class IC antiarrhythmic agent, were studied in 25 patients (mean age 61 +/- 11) with complex symptomatic ventricular arrhythmia and left ventricular dysfunction. Ninety-two percent had previous myocardial infarction and 8% had dilated cardiomyopathy. Seventy-five percent had congestive heart failure, class III or IV, according to the New York Heart Association. All patients underwent a nuclear ventriculogram performed at least 3 days after discontinuing previous antiarrhythmic drugs. Nuclear ventriculograms were repeated 1 to 6 weeks later while the patients were receiving therapeutic doses of encainide ranging from 75 to 300 [corrected] mg/day. Nuclear ventriculograms were also repeated after 6 months or 1 year of encainide therapy in 16 of these patients. Encainide did not have significant effects on heart rate, blood pressure, left ventricular ejection fraction, systolic or end-diastolic volumes. None of the patients showed a worsening of congestive heart failure during encainide therapy. These results compare favorably with those of other class I antiarrhythmic agents. A review of published reports on the hemodynamic effects of intravenous encainide shows it to have a mild but statistically significant dose-related depressant effect on cardiac function. This effect, however, appears to be no different from that of other newer class I agents.
Notes
Erratum In: Am J Cardiol 1988 Nov 15;62(16):1152
PubMed ID
3092616 View in PubMed
Less detail

[Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology]

https://arctichealth.org/en/permalink/ahliterature30053
Source
Akush Ginekol (Sofiia). 2004;43 Suppl 2:32-5
Publication Type
Article
Date
2004
Author
S. Tanchev
F. Pandurski
A. Georgiev
Iu Gesheva
V. Platikanov
P. Dinov
Source
Akush Ginekol (Sofiia). 2004;43 Suppl 2:32-5
Date
2004
Language
Bulgarian
Publication Type
Article
Keywords
Adult
Child
English Abstract
Factor VII - administration & dosage - therapeutic use
Female
Genital Diseases, Female - blood - drug therapy
Hemorrhage - blood - drug therapy
Hemostasis - drug effects
Humans
Injections, Intravenous
Middle Aged
Recombinant Proteins - administration & dosage - therapeutic use
Treatment Outcome
Abstract
We report our clinical opinion for recombinant activated factor VII (NovoSeven, Novo Nordisk, Copenhagen, Denmark) administration in gynecology patients with massive haemorrhage. 3 women with gynecology deseases and severe bleeding in recieved NovoSeven in bolus IV. The blood loss and laboratory changes in hematology and haemostasis parameters are monitored. The bleeding was ceased in all cases. Decrease in values of Hb, Er and PTT was noted. The use of recombinant factor VIIA in gynecology patients with severe bleeding is effective and safe enough and could be an alternative to the extreme surgical procedures.
PubMed ID
15518274 View in PubMed
Less detail

Adrenomedullary catecholamine, pressor and chronotropic responses to human coagulation beta-FXIIa mediated by endogenous kinins.

https://arctichealth.org/en/permalink/ahliterature93828
Source
J Hypertens. 2008 Jan;26(1):61-9
Publication Type
Article
Date
Jan-2008
Author
Amfilochiadis Akis A
Backx Peter H
Floras John S
Author Affiliation
University Health Network and Mount Sinai Hospital Division of Cardiology, Department of Medicine, Canada.
Source
J Hypertens. 2008 Jan;26(1):61-9
Date
Jan-2008
Language
English
Publication Type
Article
Keywords
Adrenal Medulla - drug effects - physiology
Animals
Blood Pressure - drug effects
Bradykinin - blood - pharmacology
Catecholamines - blood
Dose-Response Relationship, Drug
Epinephrine - blood
Factor XIIa - pharmacology
Heart Rate - drug effects
Humans
Injections, Intravenous
Kininogens - blood - deficiency
Male
Norepinephrine - blood
Peptide Fragments - pharmacology
Rats
Rats, Inbred BN
Rats, Mutant Strains
Rats, Wistar
Time Factors
Abstract
OBJECTIVES: There is increasing evidence that blood coagulation factors can influence blood pressure. In the present study, we tested the hypothesis that the beta fragment of human coagulation factor XIIa (beta-FXIIa) induces adrenal catecholamine-mediated pressor and chronotropic responses via bradykinin generated from the plasma kallikrein-kinin system. METHODS AND RESULTS: In anaesthetized bioassay rats with blocked autonomic reflexes, in the Brown Norway strain a bolus injection of beta-FXIIa (1 microg/kg, administered intravenously) elicited a 170-fold rise in plasma epinephrine (from 0.12 +/- 0.02 to 20.58 +/- 2.42 nmol/l; P
PubMed ID
18090541 View in PubMed
Less detail

Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.

https://arctichealth.org/en/permalink/ahliterature164482
Source
Pharmacotherapy. 2007 Apr;27(4):494-503
Publication Type
Article
Date
Apr-2007
Author
Matthew P Muller
Linda Dresser
Janet Raboud
Allison McGeer
Elizabeth Rea
Susan E Richardson
Tony Mazzulli
Mark Loeb
Marie Louie
Author Affiliation
Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. mmuller@mtsinai.on.ca
Source
Pharmacotherapy. 2007 Apr;27(4):494-503
Date
Apr-2007
Language
English
Publication Type
Article
Keywords
Adrenal Cortex Hormones - adverse effects - therapeutic use
Adult
Adverse Drug Reaction Reporting Systems - statistics & numerical data
Anemia - chemically induced
Antiviral Agents - administration & dosage - adverse effects - therapeutic use
Bradycardia - chemically induced
Canada - epidemiology
Cohort Studies
Disease Outbreaks
Dose-Response Relationship, Drug
Female
Humans
Injections, Intravenous
Magnesium Deficiency - chemically induced
Male
Medical Records Systems, Computerized - statistics & numerical data
Middle Aged
Retrospective Studies
Ribavirin - administration & dosage - adverse effects - therapeutic use
Severe Acute Respiratory Syndrome - drug therapy - epidemiology
Tetany - chemically induced
Treatment Outcome
Abstract
To distinguish adverse events related to ribavirin therapy from those attributable to severe acute respiratory syndrome (SARS), and to determine the rate of potential ribavirin-related adverse events.
Retrospective cohort study.
Hospitals in Toronto, Ontario, Canada.
A cohort of 306 patients with confirmed or probable SARS, 183 of whom received ribavirin and 123 of whom did not, between February 23, 2003, and July 1, 2003. Of the 183 treated patients, 155 (85%) received very high-dose ribavirin; the other 28 treated patients received lower-dose regimens.
Data on all patients with SARS admitted to hospitals in Toronto were abstracted from charts and electronic databases onto a standardized form by trained research nurses. Logistic regression was used to evaluate the association between ribavirin use and each adverse event (progressive anemia, hypomagnesemia, hypocalcemia, bradycardia, transaminitis, and hyperamylasemia) after adjusting for SARS-related prognostic factors and corticosteroid use. In the primary logistic regression analysis, ribavirin use was strongly associated with anemia (odds ratio [OR] 3.0, 99% confidence interval [CI] 1.5-6.1, p
PubMed ID
17381375 View in PubMed
Less detail

236 records – page 1 of 24.